#India #Pune #nex #Biofabrication #Enzene

Enzene Launches NeX™

Enzene, a global leader in continuous innovation and manufacturing, has recently announced the launch of NeX™, a comprehensive partnership model designed to enable governments, institutions, and biopharmaceutical organizations to establish cutting-edge biofabrication capabilities wherever they are needed. This transformative program aims to significantly increase patient access to life-saving biological products, all while maintaining cost-effectiveness.

One of the standout features of NeX™ is its reliance on Enzene's Fully-Connected Continuous Manufacturing™ platform, built upon the proven EnzeneX® methodology. This innovative approach offers a robust, scalable, and sustainable solution for the production of biological products, making it accessible and close to patients and supply chains without the high capital costs usually associated with traditional batch production facilities.

Dr. Himanshu Gadgil, CEO of Enzene, highlighted the financial benefits of this model: “A traditional biological product facility requires between $300 to $400 million to build. With our fully connected continuous manufacturing platform, we can achieve the same production capabilities for only $60 to $80 million. The efficiency derived from a compact and integrated system architecture presents long-term cost advantages and high yields for locally manufactured biopharmaceuticals. We are already in discussions with several governments and corporations around the globe and look forward to making affordable medications accessible to patients everywhere.”

The NeX program encompasses comprehensive support for the establishment and operation of biofabrication plants. This includes facility design, construction support, technology transfer, licensing of the EnzeneX platform, and ongoing operational assistance during the launch and commercialization phases. Additionally, participating organizations can access selected products from Enzene's biosimilar portfolio for regional manufacturing.

Enzene aims for the NeX initiative to help regions accelerate the establishment of local biopharmaceutical capabilities and supply chains while developing scientific talent and reducing long-term manufacturing costs for local patients. The company estimates that facilities constructed under this program could reach validation and be ready for commercial operation in less than three years.

As Enzene moves forward with the NeX initiative, it solidifies its position as an innovator in the biomanufacturing sector through its commitment to providing partners with the tools they need to succeed in delivering critical healthcare solutions. For more information about NeX and Enzene's offerings, visit www.enzene.com/nex.

About Enzene

Enzene operates as a Continuously Innovative Development and Manufacturing Organization (CIDMO™), supporting innovators and developers of biosimilars through discovery, development, and commercial supply phases. With facilities in India and the United States, Enzene provides integrated development and manufacturing services for biological products thanks to its Fully-Connected Continuous Manufacturing platform, the EnzeneX®, which boasts the world's highest yields and cost efficiencies, validated for commercial production.

To expand regional capabilities in biological product manufacturing, Enzene also provides NeX™, a collaborative program that assists governments, institutions, and biopharmaceutical organizations in establishing local biofabrication plants. Leveraging the benefits of continuous processing, NeX offers comprehensive support in facility design, technology transfer, intellectual property, training staff through its SparX™ program, ongoing operational oversight, and specific product support in various territories.

For media inquiries, please contact:
Miles Fisher-Pollard
Orientation Marketing
[email protected]